Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tilos Therapeutics Inc.

www.tilostherapeutics.com

Latest From Tilos Therapeutics Inc.

Start-Up Quarterly Statistics: Financings Fell 17% To $2.84bn In Q2

A review of second quarter biopharma start-up deal-making and financing activity from Strategic Transactions showed a quarter-over-quarter drop in dollars raised despite multiple mega-rounds, including $100m-plus VC deals for SpringWorks and Fusion.

Deals Financing

Q2 Review: Big Pharmas Weigh In On M&A, Pricing Reform

As earnings season reaches its peak, Merck, Lilly, Gilead, Amgen and Sanofi release their second quarter results. Business development remains a dominant theme. 
Sales & Earnings Biosimilars
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Hepatic (Liver)
  • Immune Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Tilos Therapeutics Inc.
  • Senior Management
  • Barbara S Fox, PhD, CEO
    Jessie English, PhD, CSO
  • Contact Info
  • Tilos Therapeutics Inc.
    Phone: (781) 728-6200
    65 Hayden Ave.
    Lexington, MA 02421
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register